10/07/20 Precios de los productores

[admin]

+3.46

[admin]

-6.54

[admin]

https://money.cnn.com/data/dow30/

[admin]

LAST CHG %CHG
DJIA 25794.77 88.68 0.34
S&P 500 3154.99 2.94 0.09
Nasdaq Composite 10527.42 -20.33 -0.19
Japan: Nikkei 225 22290.81 -238.48 -1.06
UK: FTSE 100 6082.78 33.16 0.55
Crude Oil Futures 39.83 0.21 0.53
Gold Futures 1809.70 5.90 0.33
Yen 106.71 -0.49 -0.46
Euro 1.1316 0.0031

[admin]

Gilead says remdesivir coronavirus treatment reduces risk of death in severely sick patients
PUBLISHED FRI, JUL 10 20208:50 AM EDTUPDATED 9 MIN AGO
Will Feuer
@WILLFOIA
Gilead Sciences published new data Friday on its antiviral drug remdesivir that shows it reduced the risk of death for severely sick coronavirus patients by 62% compared with standard care alone.
Shares of Gilead rose almost 3% in premarket trading Friday on the news.
Gilead said the findings must be further investigated in further trials.
WATCH NOW
VIDEO02:18
Gilead: Additional remdesivir data shows improved recovery
Gilead Sciences announced new findings Friday that its antiviral drug remdesivir reduced the risk of death for severely sick coronavirus patients by 62% compared with standard care alone.

The company said its analysis also found that remdesivir treatment was associated with “significantly improved clinical recovery.” The findings are being presented at the Virtual Covid-19 Conference as part of the 23rd International AIDS Conference, the company said.


Shares of Gilead rose more than 2% Friday on the news.

Gilead said it analyzed data from 312 patients enrolled in its phase three trial and compared it with that of 818 patients in “a real-world retrospective cohort” with similar characteristics and disease severity who received standard care alone during the same time period as the phase three trial.

“While not as vigorous as a randomized controlled trial, this analysis importantly draws from a realworld setting and serves as an important adjunct to clinical trial data, adding to our collective understanding of this virus and reflecting the extraordinary pace of the ongoing pandemic,” Dr. Susan Olender of Columbia University Irving Medical Center said in a statement.

The findings show that 7.6% of patients treated with remdesivir died compared with 12.5% of patients in the analysis who did not receive remdesivir treatment. The analysis also found that 74.4% of patients who received treatment with remdesivir recovered by day 14 compared with 59% of patients who received standard care alone.

Gilead said its findings warrant more study in additional trials.


“We are working to broaden our understanding of the full utility of remdesivir,” Gilead’s Chief Medical Officer Dr. Merdad Parsey said in a statement. “To address the urgency of the continuing pandemic, we are sharing data with the research community as quickly as possible with the goal of providing transparent and timely updates on new developments with remdesivir.”

In late April, the National Institute of Allergy and Infectious Diseases released preliminary results from its own study of remdesivir that showed patients who took remdesivir usually recovered after 11 days, four days faster than those who didn’t take the drug. However, the study did not find any statistically significant reduction in the risk of death among patients treated with remdesivir.

Gilead has previously released data from its own clinical trials of remdesivir that have also shown a hastened recovery time and a modest clinical benefit.

NIAID’s findings led the Food and Drug Administration to issue an emergency use authorization for remdesivir, allowing doctors to use the drug on hospitalized Covid-19 patients. However, the drug has not undergone the same level of review as fully FDA-authorized drugs. There are still no FDA-authorized drugs to treat Covid-19.

Last week, the company announced the much-anticipated pricing for remdesivir, saying it would charge governments of developed countries $390 per vial. That comes to a price of $2,340 per patient, considering the company expects most patients to require six vials during their care.

However, Gilead said it would charge $520 per vial for U.S. private insurance companies. The company faced some backlash for charging a higher price in the U.S., but the company defended itself, saying that’s simply a factor of the U.S. health care system.

Every drug in the U.S. has two list prices because of the country’s health-care system, Gilead CEO Daniel O’Day said in an interview last week with CNBC’s Meg Tirrell on “Squawk Box” after the announcement. He added that he stands by the pricing structure and that it will ensure access for those who need it.

The company has been donating doses to the U.S. government for distribution since it received emergency use authorization in May. The Department of Health and Human Services said last week it has secured more than 500,000 treatment courses of the drug, which it will distribute to American hospitals through September. HHS said the drug will be distributed to hospitals based on burden of Covid-19 patients.

While remdesivir was the first drug that appeared to effectively treat Covid-19 patients in a clinical study, other therapeutics have shown signs of efficacy and could threaten to make remdesivir more obsolete. Researchers at Oxford University, for example, released results from their trial last month that showed dexamethasone, a cheap and widely available steroid, can cut the risk of death by a third for Covid-19 patients on ventilators, and by a fifth for those on supplemental oxygen.

[admin]

CHG %CHG
DJIA 25814.57 108.48 0.42
S&P 500 3157.82 5.77 0.18
Nasdaq Composite 10530.35 -17.40 -0.16
Japan: Nikkei 225 22290.81 -238.48 -1.06
UK: FTSE 100 6080.49 30.87 0.51
Crude Oil Futures 39.72 0.10 0.25
Gold Futures 1810.30 6.50 0.36
Yen 106.72 -0.48 -0.45
Euro 1.1316 0

[RCHF]

Gilead asegura que el remdesivir reduce en un 62% el riesgo de muerte a los pacientes de covid más críticos

La empresa ha anunciado hoy nuevos datos sobre el análisis al fármaco


elEconomista.es

10/07/2020 - 15:34

Gilead Sciences ha publicado este viernes nuevos datos sobre la capacidad de su antiviral remdesivir en la lucha contra el coronavirus en los que asegura que muestra el medicamento redujo el riesgo de muerte para pacientes graves de covid-19 en un 62% en comparación con la atención sanitaria estándar. Las acciones suben un 2% en los primeros compases de la sesión.

"Estamos trabajando para ampliar nuestra comprensión de la utilidad total de remdesivir", ha apuntado en un comunicado recogido por la CNBC la directora médica de Gilead, Dra. Merdad Parsey.

Además, ha indicado que "para abordar la urgencia de la pandemia, estamos compartiendo datos con la comunidad de investigación lo más rápido posible con el objetivo de proporcionar actualizaciones transparentes y oportunas sobre los nuevos desarrollos con remdesivir".

Existen muchas esperanzas en torno a este medicamento para lograr un tratamiento contra el coronavirus. La semana pasada, la Unión Europea autorizó la venta de este fármaco para tratar el covid-19.

De hecho, las dudas se plantean sobre las existencias suficientes del medicamento después de que EEUU adquiriera prácticamente todo el stock disponible hasta finales de septiembre. Desde Sanidad, sin embargo, aseguran que la provisión en España está garantizada.

La fiebre del remdesivir empezó en abril al anunciar la empresa los resultados positivos de los primeros ensayos pero el momento clave fue el 26 de mayo, cuando la Agencia Europea del Medicamento avaló el fármaco de Gilead como el primer tratamiento contra el covid-19.

[RCHF]

Wall St opera dispar tras aumento récord de casos COVID-19 en EEUU
Por Medha Singh



10 jul (Reuters) - Los tres principales índices de Wall Street se movían sin dirección definida el viernes ante el nerviosismo del mercado luego de un incremento récord en los casos de coronavirus en Estados Unidos.

* A las 1413 GMT, el Promedio Industrial Dow Jones subía 51,32 puntos, o un 0,20%, a 25.757,41 unidades. El S&P 500 bajaba 1,53 puntos, o un 0,05%, a 3.150,52 y el Nasdaq Composite cedía 43,31 puntos, o un 0,41%, a 10.504,44 unidades.

* Los futuros de Wall Street subieron antes de la apertura del mercado luego de que Gilead Sciences dijo que nuevos datos de un estudio en fase avanzada mostraron que su antiviral remdesivir mejoró significativamente la recuperación clínica y redujo el riesgo de muerte en pacientes de COVID-19.

* Más de 60.500 nuevas infecciones de COVID-19 fueron notificadas en Estados Unidos el jueves, según un recuento de Reuters, un nuevo récord diario. Unos 41 de los 50 estados del país reportaron alzas en los casos en la última quincena.

* “Los inversores están prestando más atención a los descubrimientos de nuevos contagios que a los datos económicos, y ese es un patrón que hemos visto desarrollarse en las últimas dos semanas”, afirmó Art Hogan, estratega de National Securities.

* Un conjunto de datos económicos, incluyendo una adición récord en las nóminas mensuales, apunta a una reactivación de la actividad empresarial en junio, avivando una subida en las bolsas estadounidenses conducida por los estímulos.

* El S&P 500 ha trepado más de un 40% desde sus mínimos de marzo y se mantiene un 8% por debajo del máximo récord que alcanzó en febrero.

* El sector de tecnología era el mayor lastre en los tres índices principales, un día después de que impulsó al Nasdaq a su tercer máximo de cierre en esta semana. El sector de bancos ganaba un 2,2% antes de la presentación de resultados la semana próxima.

[admin]

Rally


LAST CHG %CHG
DJIA 26040.14 334.05 1.30
S&P 500 3181.23 29.18 0.93
Nasdaq Composite 10594.48 46.73 0.44
Japan: Nikkei 225 22290.81 -238.48 -1.06
UK: FTSE 100 6095.41 45.79 0.76
Crude Oil Futures 40.52 0.90 2.27
Gold Futures 1801.90 -1.90 -0.11
Yen 106.93 -0.27 -0.25
Euro 1.1300

[admin]

Dow jumps 350 points on virus treatment hope, Netflix leads Nasdaq to another record
PUBLISHED THU, JUL 9 20206:00 PM EDTUPDATED 5 MIN AGO
Fred Imbert
@FOIMBERT
WATCH NOW
VIDEO03:36
Stocks rose after positive news on a Covid-19 treatment —Here’s what three experts are saying about the markets
Stocks rose Friday as news about a potential coronavirus treatment increased hope for an economic recovery following the outbreak.

The Dow Jones Industrial Average traded 350 points higher, or more than 1%. The S&P 500 climbed 0.9%. The Nasdaq Composite rose 0.5% to another all-time high, lifted by Amazon and Netflix.


Gilead Sciences said its coronavirus treatment candidate, remdesivir, “was associated with an improvement in clinical recovery and a 62 percent reduction in the risk of mortality compared with standard of care.” The news sent Gilead shares up more than 1%. BioNTech’s CEO also told The Wall Street Journal the company’s coronavirus vaccine candidate could be ready for approval by December. The company’s U.S.-listed shares rose 5%.

Shares of companies that would benefit from the reopening outperformed. American Airlines and United gained more than 6% each. Delta traded 5.9% higher. Southwest jumped 5.2%. Cruise operator Carnival surged 9.4% after the company said it can break even in cash flow with capacity between 30% and 50%.

Netflix jumped more than 8% to a record after Goldman said it now sees a 30% rally over the next 12 months for the company. Amazon also gained 0.5% to an all-time high after Citi hiked its target on the e-commerce giant to a Street high of $3,550 per share.


Goldman Sachs was the biggest points contributor in the Dow, rising more than 4% and accounting for 56 points of the average’s total gains. Citigroup and Wells Fargo advanced more than 5% each.

“On days in which there’s promise of health solution, or that the economy might actually recover faster than expected, you tend to get all your cyclical stocks ... leading the charge,” said Michael Arone, chief investment strategist for State Street Global Advisors. Conversely, “when it looks like the economy is going to stall, or the recovery will be slower than expected, investors tend to go back to the old growth stalwarts of technology.”

Friday’s gains put the Dow up 0.9% for the week. The S&P 500 and Nasdaq were up 1.7% and 3.9% in that time period. For the year, the Dow and the S&P 500 are down 3.4% and 0.2%, respectively, while the Nasdaq is up more than 5%.

To be sure, some investors remain concerned as coronavirus cases continue to pile up. The U.S. reported Thursday more than 63,000 additional coronavirus cases, a record. The country’s seven-day average now stands at more than 53,000 cases.

“For the US, the outlook is bleak – the COVID crisis continues to metastasize as transmissions stay elevated while hospitalizations and fatalities rise too,” said Adam Crisafulli of Vital Knowledge, in a note. “While US bulls hang on to ‘Amazon, a vaccine, and the Fed’ and those three items will prevent a steep decline, it’s very hard to look at the SPX and find it near-term compelling.”

— CNBC’s Yun Li contributed reporting.

Subscribe to CNBC PRO for exclusive insights and analysis, and live business day programming from arou

[admin]

LAST CHG %CHG
DJIA 26074.75 368.66 1.43
S&P 500 3184.92 32.87 1.04
Nasdaq Composite 10617.44 69.69 0.66
Japan: Nikkei 225 22290.81 -238.48 -1.06
UK: FTSE 100 6095.41 45.79 0.76
Crude Oil Futures 40.51 0.89 2.25
Gold Futures 1802.40 -1.40 -0.08
Yen 106.93 -0.27 -0.25
Euro 1.1300 0.0015

[admin]

The S&P 500 flashed a bullish signal. Its 50-day moving average broke above the 200-day line on Thursday for the first time since late March's selloff, forming a so-called golden cross. The technical pattern has corresponded with the end of every major bear market in the last 70 years, according to Sundial Capital Research.

[admin]

https://www.wsj.com/articles/markets-do ... 98?mod=mhp